
A needle-free spray called Neffy delivers epinephrine into the nostril during a severe allergic reaction, yet one Florida healthcare professional says she keeps hitting a wall trying to get it covered for her patients.
According to News4JAX, the healthcare worker said she has submitted prior authorization requests for Neffy, particularly for young patients, and started receiving repeated denials, especially from Florida Blue. She said an insurer representative told her Neffy would only be approved if the patient had already tried the EpiPen and it had not worked — a bar she said could require proving a life-threatening outcome before the nasal spray would even be considered.
Neffy is FDA-approved for life-threatening allergic reactions and delivers epinephrine. Advocates say it offers an alternative for patients who are afraid of needles and for children too young to safely self-administer an injection. A traditional EpiPen, by contrast, is an injectable epinephrine option.
Florida Blue Defends Its Coverage Stance
Florida Blue told the station it covers injectable epinephrine and that Neffy has not been shown to work better than an injectable, while costing two to three times more. The insurer said members with a documented medical or anxiety-related reason can work with their physician to request a coverage review for the nasal spray rather than being automatically approved.
Florida Blue appears on ARS Pharma's own published coverage list as a plan with restricted access to Neffy, according to the same News4JAX report. ARS Pharmaceuticals, Neffy's manufacturer, publishes an insurer coverage chart showing plans with unrestricted coverage, prior authorization requirements, or outright coverage blocks pending an exception request. That chart, dated October 10, 2025, listed Florida Blue among the plan names tracked, and the company advises patients whose plan does not cover Neffy to contact their insurer or their employer's human resources department.
A Healthcare Worker Objects to the Requirement
The healthcare worker who spoke with the station echoed that frustration, saying epinephrine should not be treated like other medications subject to standard formulary hurdles, since it can be the difference between life and death in an emergency.
One Family's Experience With Both Options
Anna Mountaredes has two children with severe food allergies, and her family practices emergency injection drills at home so everyone knows what to do if a reaction strikes. She said the traditional EpiPen has worked for her family and that repeated practice helps them respond using muscle memory in a crisis. Neffy is another needle-free option for patients who are afraid of injections.
What Coverage Looks Like Beyond Florida Blue
Florida's Medicaid program added Neffy to its unrestricted formulary effective July 1, 2026, according to a statement from ARS Pharmaceuticals investor relations. The same statement noted that no new commercial formulary additions or coverage decisions for Neffy were issued industry-wide in the July 1, 2026 cycle, suggesting the insurance landscape for commercially insured patients has largely held steady. For patients without coverage, a $199 cash price for two devices is available through BlinkRx and GoodRx.
Coverage criteria elsewhere illustrate how restrictive insurer rules can get. A Blue Cross Blue Shield of Arizona pharmacy guideline — which applies only to that insurer's commercial and Marketplace plans, not Florida Blue — requires patients to show failure, an FDA-label contraindication, intolerance, or ineligibility for an epinephrine auto-injector, plus either a documented phobia or an inability to self-administer correctly. That guideline also requires the prescriber to be an allergist or immunologist, or to consult with one, and limits initial approval to 12 months or the end of the plan year.
National figures compiled by SnackSafely.com in a February 2025 update found that most commercially insured patients encountered coverage barriers to obtaining Neffy, with 52% of patients in a category where insurers blocked coverage outright without prior authorization, while 30% had preferred unrestricted coverage.









